Cargando…
Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious global public health problems. Characterization of the immune response, particularly antibodies to SARS-CoV-2, is important for establishing vaccine strategies. The purpose of this stu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833093/ https://www.ncbi.nlm.nih.gov/pubmed/36509045 http://dx.doi.org/10.4269/ajtmh.22-0448 |
_version_ | 1784868182641606656 |
---|---|
author | Assaid, Najlaa Arich, Soukaina Charoute, Hicham Akarid, Khadija Anouar Sadat, Mohamed Maaroufi, Abderrahmane Ezzikouri, Sayeh Sarih, M’hammed |
author_facet | Assaid, Najlaa Arich, Soukaina Charoute, Hicham Akarid, Khadija Anouar Sadat, Mohamed Maaroufi, Abderrahmane Ezzikouri, Sayeh Sarih, M’hammed |
author_sort | Assaid, Najlaa |
collection | PubMed |
description | Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious global public health problems. Characterization of the immune response, particularly antibodies to SARS-CoV-2, is important for establishing vaccine strategies. The purpose of this study was to evaluate longitudinally the kinetics of anti-SARS-CoV-2 antibodies against spike protein (S1) for up to 3 months in a cohort of 169 COVID-19 patients. We enrolled COVID-19 patients at two regional hospitals in Casablanca, Morocco, between March and September 2021. Blood samples were collected and N-specific IgM and S-specific IgG levels were measured by a commercial Euroimmun ELISA. IgM antibodies were assessed 2–5 (D00), 9–12 (D07), 17–20 (D15), and 32–37 (D30) days after symptom onset; IgG antibodies were assessed at these time points plus 60 (D60) and 90 (D90) days after symptom onset. We found that at 3 months after symptom onset, 79% of patients had detectable SARS-CoV-2-specific IgG antibodies, whereas their IgM seropositivity was 19% by 1 month after symptom onset. The IgM level decreased to 0.34 (interquartile range [IQR] 0.19–0.92) at 1 month after symptom onset, whereas the IgG level peaked at D30 (3.10; IQR 1.83–5.64) and remained almost stable at D90 (2.95; IQR 1.52–5.19). IgG levels were significantly higher in patients older than 50 years than in those younger than 50 at all follow-up time points (P < 0.05). Statistical analysis showed no significant difference in median anti-S1 antibody levels among infected patients based on gender or comorbidities. This study provides information on the longevity of anti-SARS-CoV-2 IgM and IgG antibodies in COVID-19 patients. |
format | Online Article Text |
id | pubmed-9833093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The American Society of Tropical Medicine and Hygiene |
record_format | MEDLINE/PubMed |
spelling | pubmed-98330932023-01-17 Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients Assaid, Najlaa Arich, Soukaina Charoute, Hicham Akarid, Khadija Anouar Sadat, Mohamed Maaroufi, Abderrahmane Ezzikouri, Sayeh Sarih, M’hammed Am J Trop Med Hyg Research Article Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious global public health problems. Characterization of the immune response, particularly antibodies to SARS-CoV-2, is important for establishing vaccine strategies. The purpose of this study was to evaluate longitudinally the kinetics of anti-SARS-CoV-2 antibodies against spike protein (S1) for up to 3 months in a cohort of 169 COVID-19 patients. We enrolled COVID-19 patients at two regional hospitals in Casablanca, Morocco, between March and September 2021. Blood samples were collected and N-specific IgM and S-specific IgG levels were measured by a commercial Euroimmun ELISA. IgM antibodies were assessed 2–5 (D00), 9–12 (D07), 17–20 (D15), and 32–37 (D30) days after symptom onset; IgG antibodies were assessed at these time points plus 60 (D60) and 90 (D90) days after symptom onset. We found that at 3 months after symptom onset, 79% of patients had detectable SARS-CoV-2-specific IgG antibodies, whereas their IgM seropositivity was 19% by 1 month after symptom onset. The IgM level decreased to 0.34 (interquartile range [IQR] 0.19–0.92) at 1 month after symptom onset, whereas the IgG level peaked at D30 (3.10; IQR 1.83–5.64) and remained almost stable at D90 (2.95; IQR 1.52–5.19). IgG levels were significantly higher in patients older than 50 years than in those younger than 50 at all follow-up time points (P < 0.05). Statistical analysis showed no significant difference in median anti-S1 antibody levels among infected patients based on gender or comorbidities. This study provides information on the longevity of anti-SARS-CoV-2 IgM and IgG antibodies in COVID-19 patients. The American Society of Tropical Medicine and Hygiene 2023-01 2022-12-12 /pmc/articles/PMC9833093/ /pubmed/36509045 http://dx.doi.org/10.4269/ajtmh.22-0448 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Assaid, Najlaa Arich, Soukaina Charoute, Hicham Akarid, Khadija Anouar Sadat, Mohamed Maaroufi, Abderrahmane Ezzikouri, Sayeh Sarih, M’hammed Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients |
title | Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients |
title_full | Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients |
title_fullStr | Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients |
title_full_unstemmed | Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients |
title_short | Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients |
title_sort | kinetics of sars-cov-2 igm and igg antibodies 3 months after covid-19 onset in moroccan patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833093/ https://www.ncbi.nlm.nih.gov/pubmed/36509045 http://dx.doi.org/10.4269/ajtmh.22-0448 |
work_keys_str_mv | AT assaidnajlaa kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients AT arichsoukaina kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients AT charoutehicham kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients AT akaridkhadija kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients AT anouarsadatmohamed kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients AT maaroufiabderrahmane kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients AT ezzikourisayeh kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients AT sarihmhammed kineticsofsarscov2igmandiggantibodies3monthsaftercovid19onsetinmoroccanpatients |